The Evidence-Based Guide to Antipsychotic Medications


Book Description

The Evidence-Based Guide to Antipsychotic Medications is designed to provide both clinicians and residents with focused, comprehensive, and clinically relevant information regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions -- from mood and anxiety disorders to substance abuse, personality disorders, and schizophrenia. The volume editor is a renowned psychiatrist and author with more than 25 years of experience in both clinical and research settings diagnosing and treating patients with mood and psychotic disorders. In addition, each of the volume's 13 contributors is an expert with many years of clinical experience to draw on.The book is down-to-earth and reader-friendly and is structured for maximal utility in both coverage and format: Key Clinical Points cap each chapter, synthesizing and summarizing the knowledge you can take away, and serving both as a refresher for those using the book as a reference and as a study aid to master the material. Both FDA-approved and off-label use of antipsychotic medications are addressed, reflecting the reality of clinical practice on the front lines. Use of antipsychotic medications in both the pediatric and geriatric populations, a potentially controversial subject, is addressed in a nonsensational, straight-forward manner. The Appendixes provide a wealth of information in tabular format, including drug tables (names, strengths, formulations, pharmacokinetics, and dosing); advice on initiating and monitoring antipsychotic medications; common side effects and their management; and special considerations for use during pregnancy and breastfeeding. The Evidence-Based Guide to Antipsychotic Medications is the first in a new series that strives to take evidence-based psychiatry from gold standard to standard practice. Scientifically up-to-date and rigorous, yet accessible and easy to understand, this volume stands alone as an indispensable resource on the topic.




The Evidence-Based Guide to Antidepressant Medications


Book Description

The second book in the Evidence-Based Guides series, The Evidence-Based Guide to Antidepressant Medications, provides a clear reference to the current knowledge and evidence base for the use of antidepressants among a variety of patients across a wide range of disorders. Chapters within this guide are authored by experts in their respective areas of practice, and synthesize a large amount of medical literature into a comprehensive, yet understandable, concise, reader-friendly guide. Each chapter covers both the FDA-approved and off-label use of antidepressant medications and the evidence base for their use. Each chapter also features useful tables pertaining to specific topics, such as summaries of uses and efficacy, and important clinical pearls of wisdom in the Key Clinical Concepts. Topics covered in chapters within this text include: Use of selective serotonin reuptake inhibitors, MAOIs, and tricyclic antidepressants in major depressive disorder, bipolar depression, psychotic depression, and treatment-resistant depression. Acute management of anxiety disorders, obsessive-compulsive disorder, and specific phobias through antidepressant use. Use of antidepressant medication in medically ill patients, such as those with cardiovascular, pulmonary, gastrointestinal, renal, and endocrine diseases, as well as cancer, chronic pain, HIV, burns and hospital-based trauma. Developmental considerations necessary to keep in mind when prescribing antidepressants to children and adolescents, along with an outline of controlled studies and their special attention to safety. Medication management in geriatric patients, including antidepressant use among depressed elderly patients with dementia, stroke, or Parkinson's disease. Risks and benefits of prescribing antidepressants during pregnancy and lactation. Together, the authors have synthesized a large amount of medical literature into a comprehensive, yet understandable, concise, reader-friendly guide. The Evidence-Based Guide to Antidepressant Medications is a must-have reference for psychiatrists and other practicing clinicians, residents in training, psychiatric nurses, social workers and researchers.




The Evidence-based Guide to Antidepressant Medications


Book Description

"The Evidence-Based Guide to Antipsychotic Medications" is a table-rich, comprehensive overview of current knowledge regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions, from anxiety disorders to schizophrenia.




A Guide to the Extrapyramidal Side Effects of Antipsychotic Drugs


Book Description

A very readable and well illustrated 1999 clinical guide to the common side effects of antipsychotic medication.




Breakthroughs in Antipsychotic Medications


Book Description

For people with schizophrenia and other psychotic disorders,antipsychotic medications are the key to recovery.







The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia


Book Description

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.




Schizophrenia Treatment Outcomes


Book Description

This book analyzes schizophrenia management in the context of recent clinical therapeutic advances that have transformed the measurements and outcomes landscape. Unlike any other resource, this volume carefully develops the social and clinical guidelines that affect the life of the patient and defines its role in schizophrenia treatment outcomes. The text begins by determining the concepts, development, neuroscience, and guidelines for positive outcomes before analyzing the gaps in the literature. The text addresses medical concerns in relation to outcomes in schizophrenic patients, including substance use, impact from antipsychotic medications, and medical comorbidities. The text also covers external determinants that may inhibit positive outcomes, including cultural factors, stigma, and environmental issues. Written by experts in schizophrenia care, this book compiles sound research, current clinical trends, and modern measurement markers into a well-organized compendium that delivers this data into a practical guide for measuring treatment outcomes in patients suffering from the disease. Schizophrenia Treatment Outcomes is the ultimate guide for psychiatrists, psychologists, nurses, social workers, and all medical practitioners interested in improving outcomes for schizophrenia patients.




Prescriber's Guide: Antipsychotics


Book Description

This spin-off from Stephen M. Stahl's new, completely revised, and fully updated sixth edition of the Prescriber's Guide covers the most important drugs in use today for treating patients suffering from psychotic illness. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber's Guide combines evidence-based information with clinically informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.




Guidance on Strategies to Promote Best Practice in Antipsychotic Prescribing for Children and Adolescents


Book Description

The safe and effective use of antipsychotic medications for children and adolescents [hereafter youth] in the United States is a critical issue in mental and substance use treatment. Antipsychotic medication use is substantially higher for youth in the United States when compared to rates of use among youth in most other developed countries. In response to the emergence of safety concerns in pediatric antipsychotic medication use, Federal, State, and public